



**Thermo Fisher Scientific
Genico Media Statement
October 5, 2022**

Thermo Fisher Scientific understands and shares the concerns of the families involved in the Genico matter regarding the umbilical cord blood samples stored at our facility.

To comply with patient privacy laws and regulations, it is standard practice for patient sample storage to be blinded. As such, the cord blood samples provided to us from Genico use a unique identifier that does not contain personally identifiable information and we are not able to independently identify and match donor names to samples.

The Bankruptcy Office is working with Genico to obtain the necessary patient sample information. In addition, we are actively working with the Bankruptcy Court of Locarno and District Court of Locarno-Campagna and have requested intervention from the Swiss Agency for Therapeutic Products (Swissmedic).

While we wait for further direction from the authorities, we will continue to store the samples safely and remain committed to finding a solution that safeguards the interests of the families and integrity of their samples.